HealthDay News — For patients with desmoplastic melanoma, neoadjuvant treatment with pembrolizumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, results in a pathological complete response ...
Unprotected sun exposure and indoor tanning are major contributors to melanoma incidence, highlighting the need for UV protection. Estimates show melanoma diagnoses continuing to climb in the United ...
Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 ...
The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...
New mole after 50? The ABCDE rule could save your life You notice a dark spot on your arm that wasn’t there last month. Approximately 70 ...
Lymph node dissection, the standard surgical treatment for melanoma, does not increase patient survival rates, according to a study published in The New England Journal of Medicine. Lymph node ...
Iovance Biotherapeutics announced positive five-year results from its Phase 2 C-144-01 clinical trial for Amtagvi® (lifileucel), a T cell therapy for advanced melanoma patients who previously received ...
Regional anesthesia can improve survival rates in patients with malignant melanoma, the deadliest form of skin cancer, according to a study presented at this year’s American Society of ...
The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...
The American Cancer Society released its annual statistics report that shows significant progress in cancer survival rates ...
Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results